Asian Pacific Journal of Cancer Prevention

Author = Zahra Esfahani-Monfared

Clinical Effectiveness of Erlova in EGFR-Mutated Non-Small Cell Lung Cancer: An Affordable Price with Clinical Benefit

Volume 23, Issue 4, April 2022, Pages 1155-1158

Sharareh Seifi; Babak Salimi; Zahra Esfahani-Monfared; Ramin Radmanesh; Saeed Yaghoubifard; Sara Talebianpour; Adnan Khosravi

Cell Free Tumoral DNA Versus Paraffin Block Epidermal Growth Factor Receptor Mutation Detection in Patients with Non-Small Cell Lung Cancer

Volume 20, Issue 12, December 2019, Pages 3591-3596

Hanifeh Mirtavoos-Mahyari; Mohsen Ghadami; Adnan Khosravi; Zahra Esfahani-Monfared; Sharareh Seifi; Elaheh Motevaseli; Mihan Pourabdollah; Mohammadhossein Modarressi

A Phase IV Efficacy Study of Formeta Plus Carboplatin as First-Line Treatment of Advanced Non-Squamous, Non-Small Cell Lung Cancer in Iran: An Affordable Price with Clinical Benefit

Volume 19, Issue 10, October 2018, Pages 2973-2978

Adnan Khosravi; Babak Salimi; Zahra Esfahani-Monfared; Sharareh Seifi; Hanifeh Mirtavoos-Mahyari

Analysis of Cisplatin-Induced Ototoxicity Risk Factors in Iranian Patients with Solid Tumors: a Cohort, Prospective and Single Institute Study

Volume 18, Issue 3, March 2017, Pages 753-758

Zahra Esfahani-Monfared; Adnan Khosravi; Ali Safavi Naini; Golnar Radmand; Kian Khodadad

Clinical Effectiveness of Erlova in EGFR-Mutated Non-Small Cell Lung Cancer: An Affordable Price with Clinical Benefit

Cell Free Tumoral DNA Versus Paraffin Block Epidermal Growth Factor Receptor Mutation Detection in Patients with Non-Small Cell Lung Cancer

A Phase IV Efficacy Study of Formeta Plus Carboplatin as First-Line Treatment of Advanced Non-Squamous, Non-Small Cell Lung Cancer in Iran: An Affordable Price with Clinical Benefit

Analysis of Cisplatin-Induced Ototoxicity Risk Factors in Iranian Patients with Solid Tumors: a Cohort, Prospective and Single Institute Study

Journal Archive